

# Global Hospital-Acquired Pneumonia (HAP) Drugs Market Insights, Forecast to 2029

<https://marketpublishers.com/r/G3EFE268C2CBEN.html>

Date: November 2023

Pages: 135

Price: US\$ 4,900.00 (Single User License)

ID: G3EFE268C2CBEN

## Abstracts

This report presents an overview of global market for Hospital-Acquired Pneumonia (HAP) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Hospital-Acquired Pneumonia (HAP) Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Hospital-Acquired Pneumonia (HAP) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hospital-Acquired Pneumonia (HAP) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Hospital-Acquired Pneumonia (HAP) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Hospital-Acquired Pneumonia (HAP) Drugs sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Pfizer, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Shinogi, Sun Pharmaceutical Industries and The Medicines Company, etc.

### By Company

Pfizer

Merck

Mylan

Novartis

Teva Pharmaceutical Industries

AstraZeneca

Shinogi

Sun Pharmaceutical Industries

The Medicines Company

Theravance Biopharma

### Segment by Type

Antibacterial

Antiviral

Antifungal

### Segment by Application

Hospitals

Clinics

Others

## Segment by Region

US & Canada

U.S.

Canada

China

Asia (excluding China)

Japan

South Korea

China Taiwan

Southeast Asia

India

Europe

Germany

France

U.K.

Italy

Russia

Middle East, Africa, Latin America

Brazil

Mexico

Turkey

Israel

GCC Countries

## Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Hospital-Acquired Pneumonia (HAP) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 3: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.

Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.

Chapter 8: China by type, by application sales and revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.

Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hospital-Acquired Pneumonia (HAP) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: The main points and conclusions of the report.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Pest Control & Exterminator Services Market Size Growth Rate by Type:  
2018 VS 2022 VS 2029

1.2.2 Prevent Services

1.2.3 Protect Services

1.3 Market by Application

1.3.1 Global Pest Control & Exterminator Services Market Growth by Application: 2018  
VS 2022 VS 2029

1.3.2 Indoor

1.3.3 Outdoor

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

### 2 GLOBAL GROWTH TRENDS

2.1 Global Pest Control & Exterminator Services Market Perspective (2018-2029)

2.2 Pest Control & Exterminator Services Growth Trends by Region

2.2.1 Global Pest Control & Exterminator Services Market Size by Region: 2018 VS  
2022 VS 2029

2.2.2 Pest Control & Exterminator Services Historic Market Size by Region  
(2018-2023)

2.2.3 Pest Control & Exterminator Services Forecasted Market Size by Region  
(2024-2029)

2.3 Pest Control & Exterminator Services Market Dynamics

2.3.1 Pest Control & Exterminator Services Industry Trends

2.3.2 Pest Control & Exterminator Services Market Drivers

2.3.3 Pest Control & Exterminator Services Market Challenges

2.3.4 Pest Control & Exterminator Services Market Restraints

### 3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Pest Control & Exterminator Services Players by Revenue

3.1.1 Global Top Pest Control & Exterminator Services Players by Revenue

(2018-2023)

3.1.2 Global Pest Control & Exterminator Services Revenue Market Share by Players

(2018-2023)

3.2 Global Pest Control & Exterminator Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Pest Control & Exterminator Services Revenue

3.4 Global Pest Control & Exterminator Services Market Concentration Ratio

3.4.1 Global Pest Control & Exterminator Services Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Pest Control & Exterminator Services Revenue in 2022

3.5 Pest Control & Exterminator Services Key Players Head office and Area Served

3.6 Key Players Pest Control & Exterminator Services Product Solution and Service

3.7 Date of Enter into Pest Control & Exterminator Services Market

3.8 Mergers & Acquisitions, Expansion Plans

## **4 PEST CONTROL & EXTERMINATOR SERVICES BREAKDOWN DATA BY TYPE**

4.1 Global Pest Control & Exterminator Services Historic Market Size by Type (2018-2023)

4.2 Global Pest Control & Exterminator Services Forecasted Market Size by Type (2024-2029)

## **5 PEST CONTROL & EXTERMINATOR SERVICES BREAKDOWN DATA BY APPLICATION**

5.1 Global Pest Control & Exterminator Services Historic Market Size by Application (2018-2023)

5.2 Global Pest Control & Exterminator Services Forecasted Market Size by Application (2024-2029)

## **6 NORTH AMERICA**

6.1 North America Pest Control & Exterminator Services Market Size (2018-2029)

6.2 North America Pest Control & Exterminator Services Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Pest Control & Exterminator Services Market Size by Country (2018-2023)

6.4 North America Pest Control & Exterminator Services Market Size by Country

(2024-2029)

6.5 United States

6.6 Canada

## **7 EUROPE**

7.1 Europe Pest Control & Exterminator Services Market Size (2018-2029)

7.2 Europe Pest Control & Exterminator Services Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Pest Control & Exterminator Services Market Size by Country (2018-2023)

7.4 Europe Pest Control & Exterminator Services Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Pest Control & Exterminator Services Market Size (2018-2029)

8.2 Asia-Pacific Pest Control & Exterminator Services Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Pest Control & Exterminator Services Market Size by Region (2018-2023)

8.4 Asia-Pacific Pest Control & Exterminator Services Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

## **9 LATIN AMERICA**

9.1 Latin America Pest Control & Exterminator Services Market Size (2018-2029)

9.2 Latin America Pest Control & Exterminator Services Market Growth Rate by Country: 2018 VS 2022 VS 2029



9.3 Latin America Pest Control & Exterminator Services Market Size by Country (2018-2023)

9.4 Latin America Pest Control & Exterminator Services Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Pest Control & Exterminator Services Market Size (2018-2029)

10.2 Middle East & Africa Pest Control & Exterminator Services Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Pest Control & Exterminator Services Market Size by Country (2018-2023)

10.4 Middle East & Africa Pest Control & Exterminator Services Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

## **11 KEY PLAYERS PROFILES**

11.1 Anderson

11.1.1 Anderson Company Detail

11.1.2 Anderson Business Overview

11.1.3 Anderson Pest Control & Exterminator Services Introduction

11.1.4 Anderson Revenue in Pest Control & Exterminator Services Business (2018-2023)

11.1.5 Anderson Recent Development

11.2 Aptive

11.2.1 Aptive Company Detail

11.2.2 Aptive Business Overview

11.2.3 Aptive Pest Control & Exterminator Services Introduction

11.2.4 Aptive Revenue in Pest Control & Exterminator Services Business (2018-2023)

11.2.5 Aptive Recent Development

11.3 Ardent Pest Control

11.3.1 Ardent Pest Control Company Detail

11.3.2 Ardent Pest Control Business Overview

- 11.3.3 Ardent Pest Control Pest Control & Exterminator Services Introduction
- 11.3.4 Ardent Pest Control Revenue in Pest Control & Exterminator Services Business (2018-2023)
- 11.3.5 Ardent Pest Control Recent Development
- 11.4 Arrow Exterminators
  - 11.4.1 Arrow Exterminators Company Detail
  - 11.4.2 Arrow Exterminators Business Overview
  - 11.4.3 Arrow Exterminators Pest Control & Exterminator Services Introduction
  - 11.4.4 Arrow Exterminators Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.4.5 Arrow Exterminators Recent Development
- 11.5 Bain Pest Control
  - 11.5.1 Bain Pest Control Company Detail
  - 11.5.2 Bain Pest Control Business Overview
  - 11.5.3 Bain Pest Control Pest Control & Exterminator Services Introduction
  - 11.5.4 Bain Pest Control Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.5.5 Bain Pest Control Recent Development
- 11.6 Bulwark
  - 11.6.1 Bulwark Company Detail
  - 11.6.2 Bulwark Business Overview
  - 11.6.3 Bulwark Pest Control & Exterminator Services Introduction
  - 11.6.4 Bulwark Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.6.5 Bulwark Recent Development
- 11.7 Clark Pest Control
  - 11.7.1 Clark Pest Control Company Detail
  - 11.7.2 Clark Pest Control Business Overview
  - 11.7.3 Clark Pest Control Pest Control & Exterminator Services Introduction
  - 11.7.4 Clark Pest Control Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.7.5 Clark Pest Control Recent Development
- 11.8 Dewey Pest Control
  - 11.8.1 Dewey Pest Control Company Detail
  - 11.8.2 Dewey Pest Control Business Overview
  - 11.8.3 Dewey Pest Control Pest Control & Exterminator Services Introduction
  - 11.8.4 Dewey Pest Control Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.8.5 Dewey Pest Control Recent Development

## 11.9 Ecola

11.9.1 Ecola Company Detail

11.9.2 Ecola Business Overview

11.9.3 Ecola Pest Control & Exterminator Services Introduction

11.9.4 Ecola Revenue in Pest Control & Exterminator Services Business (2018-2023)

11.9.5 Ecola Recent Development

## 11.10 Ehrlich

11.10.1 Ehrlich Company Detail

11.10.2 Ehrlich Business Overview

11.10.3 Ehrlich Pest Control & Exterminator Services Introduction

11.10.4 Ehrlich Revenue in Pest Control & Exterminator Services Business  
(2018-2023)

11.10.5 Ehrlich Recent Development

## 11.11 Greenix

11.11.1 Greenix Company Detail

11.11.2 Greenix Business Overview

11.11.3 Greenix Pest Control & Exterminator Services Introduction

11.11.4 Greenix Revenue in Pest Control & Exterminator Services Business  
(2018-2023)

11.11.5 Greenix Recent Development

## 11.12 Hawx

11.12.1 Hawx Company Detail

11.12.2 Hawx Business Overview

11.12.3 Hawx Pest Control & Exterminator Services Introduction

11.12.4 Hawx Revenue in Pest Control & Exterminator Services Business (2018-2023)

11.12.5 Hawx Recent Development

## 11.13 Moxie Services

11.13.1 Moxie Services Company Detail

11.13.2 Moxie Services Business Overview

11.13.3 Moxie Services Pest Control & Exterminator Services Introduction

11.13.4 Moxie Services Revenue in Pest Control & Exterminator Services Business  
(2018-2023)

11.13.5 Moxie Services Recent Development

## 11.14 Orkin Pros

11.14.1 Orkin Pros Company Detail

11.14.2 Orkin Pros Business Overview

11.14.3 Orkin Pros Pest Control & Exterminator Services Introduction

11.14.4 Orkin Pros Revenue in Pest Control & Exterminator Services Business  
(2018-2023)

- 11.14.5 Orkin Pros Recent Development
- 11.15 Saela
  - 11.15.1 Saela Company Detail
  - 11.15.2 Saela Business Overview
  - 11.15.3 Saela Pest Control & Exterminator Services Introduction
  - 11.15.4 Saela Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.15.5 Saela Recent Development
- 11.16 Terminix
  - 11.16.1 Terminix Company Detail
  - 11.16.2 Terminix Business Overview
  - 11.16.3 Terminix Pest Control & Exterminator Services Introduction
  - 11.16.4 Terminix Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.16.5 Terminix Recent Development
- 11.17 Truly Nolen
  - 11.17.1 Truly Nolen Company Detail
  - 11.17.2 Truly Nolen Business Overview
  - 11.17.3 Truly Nolen Pest Control & Exterminator Services Introduction
  - 11.17.4 Truly Nolen Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.17.5 Truly Nolen Recent Development
- 11.18 Turner Pest Control
  - 11.18.1 Turner Pest Control Company Detail
  - 11.18.2 Turner Pest Control Business Overview
  - 11.18.3 Turner Pest Control Pest Control & Exterminator Services Introduction
  - 11.18.4 Turner Pest Control Revenue in Pest Control & Exterminator Services Business (2018-2023)
  - 11.18.5 Turner Pest Control Recent Development

## **12 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **13 APPENDIX**

- 13.1 Research Methodology
  - 13.1.1 Methodology/Research Approach
  - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details



## List Of Tables

### LIST OF TABLES

Table 1. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Table 2. Major Manufacturers of Antibacterial

Table 3. Major Manufacturers of Antiviral

Table 4. Major Manufacturers of Antifungal

Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US\$ Million)

Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2018-2023) & (US\$ Million)

Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2024-2029) & (US\$ Million)

Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2018-2023)

Table 10. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2024-2029)

Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US\$ Million)

Table 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2018-2023) & (K Units)

Table 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2024-2029) & (K Units)

Table 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2018-2023)

Table 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2024-2029)

Table 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers (2018-2023) & (K Units)

Table 17. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Manufacturers (2018-2023)

Table 18. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (2018-2023) & (US\$ Million)

Table 19. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2018-2023)

Table 20. Global Key Players of Hospital-Acquired Pneumonia (HAP) Drugs, Industry Ranking, 2021 VS 2022 VS 2023

Table 21. Hospital-Acquired Pneumonia (HAP) Drugs Price by Manufacturers 2018-2023 (USD/Unit)

Table 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 23. Global Hospital-Acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Acquired Pneumonia (HAP) Drugs as of 2022)

Table 24. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Base Distribution and Headquarters

Table 25. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Product Offered and Application

Table 26. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 30. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Type (2018-2023)

Table 31. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Type (2024-2029)

Table 32. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 33. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 34. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Type (2018-2023)

Table 35. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Type (2024-2029)

Table 36. Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2018-2023) & (USD/Unit)

Table 37. Global Hospital-Acquired Pneumonia (HAP) Drugs Price Forecast by Type (2024-2029) & (USD/Unit)

Table 38. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2018-2023) & (K Units)

Table 39. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application

(2024-2029) & (K Units)

Table 40. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Application (2018-2023)

Table 41. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Application (2024-2029)

Table 42. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 43. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 44. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Application (2018-2023)

Table 45. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Application (2024-2029)

Table 46. Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2018-2023) & (USD/Unit)

Table 47. Global Hospital-Acquired Pneumonia (HAP) Drugs Price Forecast by Application (2024-2029) & (USD/Unit)

Table 48. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 49. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 50. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 51. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 52. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2018-2023) & (K Units)

Table 53. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2024-2029) & (K Units)

Table 54. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 55. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 56. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 57. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2018-2023) & (US\$ Million)

Table 58. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2024-2029) & (US\$ Million)



Table 59. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2018-2023) & (K Units)

Table 60. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2024-2029) & (K Units)

Table 61. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 62. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 63. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 64. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 65. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2018-2023) & (K Units)

Table 66. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2024-2029) & (K Units)

Table 67. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 68. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 69. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 70. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2018-2023) & (US\$ Million)

Table 71. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2024-2029) & (US\$ Million)

Table 72. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2018-2023) & (K Units)

Table 73. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2024-2029) & (K Units)

Table 74. China Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 75. China Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 76. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 77. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 78. China Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application

(2018-2023) & (K Units)

Table 79. China Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2024-2029) & (K Units)

Table 80. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 81. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 82. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 83. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 84. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 85. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 86. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2018-2023) & (K Units)

Table 87. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2024-2029) & (K Units)

Table 88. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 89. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 90. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 91. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2018-2023) & (US\$ Million)

Table 92. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2024-2029) & (US\$ Million)

Table 93. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2018-2023) & (K Units)

Table 94. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2024-2029) & (K Units)

Table 95. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2018-2023) & (K Units)

Table 96. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2024-2029) & (K Units)

Table 97. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2018-2023) & (US\$ Million)

Table 98. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2024-2029) & (US\$ Million)

Table 99. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2018-2023) & (K Units)

Table 100. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2024-2029) & (K Units)

Table 101. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2018-2023) & (US\$ Million)

Table 102. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2024-2029) & (US\$ Million)

Table 103. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 104. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2018-2023) & (US\$ Million)

Table 105. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2024-2029) & (US\$ Million)

Table 106. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2018-2023) & (K Units)

Table 107. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2024-2029) & (K Units)

Table 108. Pfizer Company Information

Table 109. Pfizer Description and Major Businesses

Table 110. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 111. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 112. Pfizer Recent Developments

Table 113. Merck Company Information

Table 114. Merck Description and Major Businesses

Table 115. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 116. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 117. Merck Recent Developments

Table 118. Mylan Company Information

Table 119. Mylan Description and Major Businesses

Table 120. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 121. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers,

Pictures, Descriptions and Specifications

Table 122. Mylan Recent Developments

Table 123. Novartis Company Information

Table 124. Novartis Description and Major Businesses

Table 125. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 126. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 127. Novartis Recent Developments

Table 128. Teva Pharmaceutical Industries Company Information

Table 129. Teva Pharmaceutical Industries Description and Major Businesses

Table 130. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 131. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 132. Teva Pharmaceutical Industries Recent Developments

Table 133. AstraZeneca Company Information

Table 134. AstraZeneca Description and Major Businesses

Table 135. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 136. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 137. AstraZeneca Recent Developments

Table 138. Shinogi Company Information

Table 139. Shinogi Description and Major Businesses

Table 140. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 141. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 142. Shinogi Recent Developments

Table 143. Sun Pharmaceutical Industries Company Information

Table 144. Sun Pharmaceutical Industries Description and Major Businesses

Table 145. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 146. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 147. Sun Pharmaceutical Industries Recent Developments

- Table 148. The Medicines Company Company Information
- Table 149. The Medicines Company Description and Major Businesses
- Table 150. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 151. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- Table 152. The Medicines Company Recent Developments
- Table 153. Theravance Biopharma Company Information
- Table 154. Theravance Biopharma Description and Major Businesses
- Table 155. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 156. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- Table 157. Theravance Biopharma Recent Developments
- Table 158. Key Raw Materials Lists
- Table 159. Raw Materials Key Suppliers Lists
- Table 160. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List
- Table 161. Hospital-Acquired Pneumonia (HAP) Drugs Customers List
- Table 162. Hospital-Acquired Pneumonia (HAP) Drugs Market Trends
- Table 163. Hospital-Acquired Pneumonia (HAP) Drugs Market Drivers
- Table 164. Hospital-Acquired Pneumonia (HAP) Drugs Market Challenges
- Table 165. Hospital-Acquired Pneumonia (HAP) Drugs Market Restraints
- Table 166. Research Programs/Design for This Report
- Table 167. Key Data Information from Secondary Sources
- Table 168. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. Hospital-Acquired Pneumonia (HAP) Drugs Product Picture
- Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)
- Figure 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2022 & 2029
- Figure 4. Antibacterial Product Picture
- Figure 5. Antiviral Product Picture
- Figure 6. Antifungal Product Picture
- Figure 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)
- Figure 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2022 & 2029
- Figure 9. Hospitals
- Figure 10. Clinics
- Figure 11. Others
- Figure 12. Hospital-Acquired Pneumonia (HAP) Drugs Report Years Considered
- Figure 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue 2018-2029 (US\$ Million)
- Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
- Figure 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2018-2029)
- Figure 17. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales 2018-2029 ((K Units)
- Figure 18. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2018-2029)
- Figure 19. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales YoY (2018-2029) & (K Units)
- Figure 20. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue YoY (2018-2029) & (US\$ Million)
- Figure 21. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales YoY (2018-2029) & (K Units)
- Figure 22. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue YoY

(2018-2029) & (US\$ Million)

Figure 23. China Hospital-Acquired Pneumonia (HAP) Drugs Sales YoY (2018-2029) & (K Units)

Figure 24. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue YoY (2018-2029) & (US\$ Million)

Figure 25. Asia (excluding China) Hospital-Acquired Pneumonia (HAP) Drugs Sales YoY (2018-2029) & (K Units)

Figure 26. Asia (excluding China) Hospital-Acquired Pneumonia (HAP) Drugs Revenue YoY (2018-2029) & (US\$ Million)

Figure 27. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales YoY (2018-2029) & (K Units)

Figure 28. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue YoY (2018-2029) & (US\$ Million)

Figure 29. The Hospital-Acquired Pneumonia (HAP) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022

Figure 30. The Top 5 and 10 Largest Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs in the World: Market Share by Hospital-Acquired Pneumonia (HAP) Drugs Revenue in 2022

Figure 31. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 32. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 33. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)

Figure 34. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 35. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 36. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 37. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)

Figure 38. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 39. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 40. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country (2018-2029)

Figure 41. US & Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by

Country (2018-2029)

Figure 42. U.S. Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 43. Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 44. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 45. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)

Figure 46. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 47. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 48. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country (2018-2029)

Figure 49. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country (2018-2029)

Figure 50. Germany Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 51. France Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 52. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 53. Italy Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 54. Russia Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 55. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 56. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)

Figure 57. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 58. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 59. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 60. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)



Figure 61. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 62. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 63. Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Region (2018-2029)

Figure 64. Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Region (2018-2029)

Figure 65. Japan Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 66. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 67. China Taiwan Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 68. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 69. India Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 70. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2018-2029)

Figure 71. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2018-2029)

Figure 72. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2018-2029)

Figure 73. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2018-2029)

Figure 74. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country (2018-2029)

Figure 75. Middle East, Africa and Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country (2018-2029)

Figure 76. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 77. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 78. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 79. Israel Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2018-2029) & (US\$ Million)

Figure 80. GCC Countries Hospital-Acquired Pneumonia (HAP) Drugs Revenue

(2018-2029) & (US\$ Million)

Figure 81. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain

Figure 82. Hospital-Acquired Pneumonia (HAP) Drugs Production Process

Figure 83. Channels of Distribution

Figure 84. Distributors Profiles

Figure 85. Bottom-up and Top-down Approaches for This Report

Figure 86. Data Triangulation

Figure 87. Key Executives Interviewed

## I would like to order

Product name: Global Hospital-Acquired Pneumonia (HAP) Drugs Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/G3EFE268C2CBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3EFE268C2CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970